- Home
- ORGO vs BRSP Comparison
ORGO vs BRSP Comparison
Compare ORGO & BRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- BRSP
- Stock Information
- Founded
- ORGO 1985
- BRSP 2017
- Country
- ORGO United States
- BRSP United States
- Employees
- ORGO N/A
- BRSP N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- BRSP Real Estate Investment Trusts
- Sector
- ORGO Health Care
- BRSP Real Estate
- Exchange
- ORGO Nasdaq
- BRSP Nasdaq
- Market Cap
- ORGO 665.8M
- BRSP 736.6M
- IPO Year
- ORGO N/A
- BRSP 2018
- Fundamental
- Price
- ORGO $4.28
- BRSP $5.54
- Analyst Decision
- ORGO Buy
- BRSP Buy
- Analyst Count
- ORGO 2
- BRSP 4
- Target Price
- ORGO $5.50
- BRSP $7.25
- AVG Volume (30 Days)
- ORGO 1.3M
- BRSP 745.3K
- Earning Date
- ORGO 05-08-2025
- BRSP 04-30-2025
- Dividend Yield
- ORGO N/A
- BRSP 11.57%
- EPS Growth
- ORGO N/A
- BRSP N/A
- EPS
- ORGO N/A
- BRSP N/A
- Revenue
- ORGO $482,043,000.00
- BRSP $358,805,000.00
- Revenue This Year
- ORGO N/A
- BRSP N/A
- Revenue Next Year
- ORGO $7.62
- BRSP $26.25
- P/E Ratio
- ORGO N/A
- BRSP N/A
- Revenue Growth
- ORGO 11.29
- BRSP N/A
- 52 Week Low
- ORGO $2.17
- BRSP $5.07
- 52 Week High
- ORGO $6.71
- BRSP $6.71
- Technical
- Relative Strength Index (RSI)
- ORGO 43.72
- BRSP 29.92
- Support Level
- ORGO $4.80
- BRSP $5.46
- Resistance Level
- ORGO $5.57
- BRSP $5.97
- Average True Range (ATR)
- ORGO 0.32
- BRSP 0.15
- MACD
- ORGO -0.15
- BRSP -0.05
- Stochastic Oscillator
- ORGO 3.73
- BRSP 13.01
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.